This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry
Annals of Hematology Open Access 03 March 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511–518.
Ferrero S, Dreyling M . The current therapeutic scenario for relapsed mantle cell lymphoma. Curr Opin Oncol 2013; 25: 452–462.
Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347–5356.
Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867–4874.
Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma mantle cell lymphoma. J Clin Oncol 2009; 27: 3822–3829.
Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416–422.
Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24: 2892–2897.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.
Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804–1810.
Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213–5218.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336–4342.
Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 30: 3119–3126.
Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood 2014; 123: 2953–2959.
Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA et al. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica 2013; 98: 1563–1570.
Acknowledgements
We thank the patients, nurses, physicians and data managers (Antonella Fiorillo). A special thanks to Marco Ladetto, MD, for the scientific and material support and to Sara Fortin for graphical assistance. This work was supported by the EU (LSHC-CT 2004-503351), the Lymphoma Research Foundation (New York) and Bayer-Schering. SF was supported by Progetto di Rilevante Interesse Nazionale (PRIN 2009) from Ministero Italiano dell' Università e della Ricerca (MIUR), Roma, Italy (code: 7.07.02.60 AE01); Progetto di Ricerca Sanitaria Finalizzata 2009, head unit: Divisione di Ematologia S Cortellazzo, AOS Maurizio, Bolzano/Bozen, Italy (code: RF-2009-1469205); Progetto di Ricerca Sanitaria Finalizzata 2010 (head unit: Divisione di Ematologia, AOS Maurizio, Bolzano/Bozen, Italy; code: RF-2010-2307262), Fondi di Ricerca Locale, Università degli Studi di Torino, Torino, Italy; Fondazione Neoplasie del Sangue (FO. NE. SA), Torino, Italy.
Author contributions
MD, MU and WH designed the study. SF, MD and PG wrote the report. MU and MD supervised the clinical conduction of the study and data analysis. SF, APa, OW and MU supervised data collection and analyzed data. OW and MU reviewed and assisted in writing the manuscript. RP did the statistical analysis. APa, RF, CWS, APe, LB, LT, JF, UK and OW recruited the patients.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
Off-label use: Zevalin for the treatment of relapsed MCL. SF: Celgene-Mundipharma, Speakers Honoraria. LT: Spectrum Pharmaceuticals, research funding; CWS: Bayer, Speakers Bureau; Spectrum, Membership on an entity‘s Board of Directors or advisory committees, Speakers Honoraria. Gilead, Janssen-Cilag, Roche, Pfizer and Mundipharma, Advisory Board; Roche, Mundipharma, Pfizer and Gilead, Speakers Honoraria; UK: Spectrum Pharmaceuticals, Advisory board, Consultancy; Roche, Advisory board, Consultancy. MD: Jannsen-Celgene-Pfizer, Membership on an entity‘s Board of Directors or advisory committees, Speakers Bureau, support of ITS; Roche, Speakers Bureau, support of ITS; Mundipharma, support of ITS. The other authors declare no conflict of interest.
Additional information
This manuscript is an original paper and has not been submitted or published elsewhere. Data from interim analyses were presented in part at the 2013 American Society of Hematology (ASH) meeting.
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Ferrero, S., Pastore, A., Scholz, C. et al. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial. Leukemia 30, 984–987 (2016). https://doi.org/10.1038/leu.2015.215
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.215
This article is cited by
-
Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry
Annals of Hematology (2020)